

Short Bio

Dr. Beavis completed his PhD at Imperial College London in 2010 and joined Peter Mac shortly thereafter to work in the Cancer Immunology Program. Dr. Beavis has now established a vibrant program of research with his own research group focussing on the molecular and biological processes involved in tumour-induced immunosuppression, in particular the role of CD73 and adenosine receptor signalling. He also has a significant interest in developing novel CAR T cell technology to enhance their effectiveness in solid cancer and has previously shown that immunotherapies such as anti-PD-1 and adenosine receptor antagonists can enhance CAR T cell function. His recent work has investigated novel methods to increase the efficacy of CAR T cells by promoting their engagement of the endogenous immune system.